SE0401790D0 - Tamoxifen response in pre- and postmenopausal breast cancer patients - Google Patents

Tamoxifen response in pre- and postmenopausal breast cancer patients

Info

Publication number
SE0401790D0
SE0401790D0 SE0401790A SE0401790A SE0401790D0 SE 0401790 D0 SE0401790 D0 SE 0401790D0 SE 0401790 A SE0401790 A SE 0401790A SE 0401790 A SE0401790 A SE 0401790A SE 0401790 D0 SE0401790 D0 SE 0401790D0
Authority
SE
Sweden
Prior art keywords
breast cancer
cancer patients
postmenopausal breast
tamoxifen response
tamoxifen
Prior art date
Application number
SE0401790A
Other languages
English (en)
Inventor
Goeran Landberg
Lisa Ryden
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Priority to SE0401790A priority Critical patent/SE0401790D0/sv
Publication of SE0401790D0 publication Critical patent/SE0401790D0/sv
Priority to PCT/SE2005/001116 priority patent/WO2006004545A1/en
Priority to EP05757471A priority patent/EP1773309A1/en
Priority to US11/620,275 priority patent/US20070213403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SE0401790A 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients SE0401790D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients
PCT/SE2005/001116 WO2006004545A1 (en) 2004-07-07 2005-07-06 Tamoxifen response in pre-and postmenopausal breast cancer patients
EP05757471A EP1773309A1 (en) 2004-07-07 2005-07-06 Tamoxifen response in pre-and postmenopausal breast cancer patients
US11/620,275 US20070213403A1 (en) 2004-07-07 2007-01-05 Tamoxifen response in pre-and postmenopausal breast cancer patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients

Publications (1)

Publication Number Publication Date
SE0401790D0 true SE0401790D0 (sv) 2004-07-07

Family

ID=32768801

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401790A SE0401790D0 (sv) 2004-07-07 2004-07-07 Tamoxifen response in pre- and postmenopausal breast cancer patients

Country Status (4)

Country Link
US (1) US20070213403A1 (sv)
EP (1) EP1773309A1 (sv)
SE (1) SE0401790D0 (sv)
WO (1) WO2006004545A1 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
EP1805155B1 (en) 2004-10-25 2010-11-03 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US20140018253A1 (en) * 2012-04-05 2014-01-16 Oregon Health And Science University Gene expression panel for breast cancer prognosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539588A (en) * 1967-12-06 1970-11-10 American Home Prod Trans-1,4,4a,5,6,11b-hexahydro-11h-benzo(a) carbazol-5-one,thiosemicarbazones
US4769378A (en) * 1986-03-31 1988-09-06 Eli Lilly And Company Indenopyrimidine aromatase inhibitors
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
AU3105700A (en) * 1998-12-08 2000-06-26 Board Of Regents, The University Of Texas System Methods for detection of antiestrogen-resistant breast cancer
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
AR034118A1 (es) * 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
EP1330251A4 (en) * 2000-10-06 2006-03-15 Intarcia Therapeutics Inc POLYTHERAPY FOR THE TREATMENT OF OESTROGENIC SENSITIVE DISEASE
CA2470480C (en) * 2001-12-27 2010-12-14 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
AU2003209119A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
EP1646382A4 (en) * 2003-06-30 2010-07-21 Hif Bio Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
WO2006004545A1 (en) 2006-01-12
EP1773309A1 (en) 2007-04-18
US20070213403A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
CY1111729T1 (el) Υπογλωσσιο επικαλυμμενο δισκιο
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
EA200900202A1 (ru) Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
MXPA03011940A (es) Ligandos del receptor de 5-ht- y sus usos.
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
HK1108702A1 (en) Ephb receptor-binding peptides ephb
CR10266A (es) Software y metodos para la planeación de tratamientos dentales
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
DK1729753T3 (da) Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet
TN2009000371A1 (fr) Composition pharmaceutique
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
SE0501903L (sv) Borföreningar användbara vid BNCT
DE602007006280D1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
NO20055207L (no) Oralt farmasoytisk preparat for protonpumpeantagonister
HUP0402281A2 (hu) Endotelin receptor antagonisták alkalmazása daganatos betegségek kezelésére alkalmas gyógyszerkészítmények előállítására